AEM-28-08

N/A

Report date: 2025/10/28 17:00:25
NME

Base Information

Drug NameAEM-28-08
Drug Alias NameAEM-28 analog (LipimetiX Development/Anji Pharma)chimeric Apo E mimetic peptide (LipimetiX Development/Anji Pharma)AEM-28-08
ClassificationSmall molecules > Peptidomimetic
Mechanisms of ActionApolipoprotein E agonists
TargetsApolipoprotein E
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHyperlipoproteinemia Type IIAcute Coronary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanHong Kong +[4] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPending
Originator CompaniesLipimetix Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesAnji PharmaceuticalsLipimetix Development Llc
Inactive CompaniesN/A
Active IndicationsHomozygous familial hypercholesterolemiaAcute Coronary Syndrome
Inactive IndicationsHyperlipoproteinemia Type II

Other Information

ATC CodeN/A
Related LinksN/A